Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398865 | 0.77 | QPCT (0.46) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL30984077 | 0.71 | FLT3 (0.34) | — | |
| SCHEMBL30984078 | 0.69 | — | — | |
| SCHEMBL7420623 | 0.69 | PARP1 (0.30) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4144530 | 0.69 | CDK1 (0.38) | ALDH1A1 | |
| SCHEMBL30983864 | 0.69 | — | — | |
| SCHEMBL29941283 | 0.67 | CHEK1 (0.36) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL6005039 | 0.67 | — | — | |
| SCHEMBL4323514 | 0.66 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL22430792 | 0.66 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410075-B2 | Mannich base N-oxide drugs | CASCADE PRODRUG INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2136626-A1 | MANNICH BASE N-OXIDE DRUGS | State of Oregon acting by and through the Oregon State Board of Higher Education on behalf of the University of Oregon (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008115499-A1 | MANNICH BASE N-OXIDE DRUGS | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 2008-09-25 | — | — | WO | disclosed |
| US-7405030-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2008-07-29 | — | — | US | disclosed |
| EP-1930339-A2 | Imide compound | MITSUI CHEMICALS, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20070259151-A1 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-7259260-B2 | Imide compound and optical recording media made by using the same | MITSUI CHEMICALS, INC. (JP) | 2007-08-21 | — | — | US | disclosed |
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20050208425-A1 | Imide compound and optical recording media made by using the same | YAMAMOTO CHEMICALS, INC. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1445115-A1 | IMIDE COMPOUNDS AND OPTICAL RECORDING MEDIA MADE BY USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | KDM4E 3453/4885ALDH1A1 1148/4885GLA 1428/4885 |
| US-20050208425-A1 | Imide compound and optical recording media made by using the same | CRY1, MTNR1A, TRPA1 | KDM4E 3011/4885ALDH1A1 1336/4885GLA 1297/4885 |
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | KDM4E 855/4885ALDH1A1 1391/4885GLA 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.